Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Patrick J. Cocke"'
Autor:
Brian A. Willis, Stephen L. Lowe, Scott A. Monk, Patrick J. Cocke, Christopher D. Aluise, Leonard N. Boggs, Anthony R. Borders, Richard A. Brier, Robert A. Dean, Steven J. Green, Douglas E. James, Stanford S. Jhee, Qun Lin, Albert C. Lo, Patrick C. May, Brian M. Watson, Leonard L. Winneroski, Zhixiang Yang, Jennifer A. Zimmer, David L. McKinzie, Dustin J. Mergott
Publikováno v:
Journal of Alzheimer's disease reports. 6(1)
Background: The development of beta-site amyloid-beta precursor protein cleaving enzyme (BACE) 1 inhibitors for the treatment of Alzheimer’s disease requires optimization of inhibitor potency, selectivity, and brain penetration. Moreover, there is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::912368ce5d97e52cb749b71026a53952
https://pubmed.ncbi.nlm.nih.gov/35243208
https://pubmed.ncbi.nlm.nih.gov/35243208
Autor:
Stephanie L. Stout, Leonard L. Winneroski, Jorg Hendle, Warren J. Porter, Patrick J. C. May, Leonard N. Boggs, Thomas K. Baker, James P. Beck, Steven James Green, Anthony R. Borders, Erik James Hembre, Stephen L. Lowe, Christopher D Aluise, David L. McKinzie, Brian Morgan Watson, Brian Michael Mathes, Jon A. Erickson, Zhixiang Yang, Patrick J Cocke, Dustin J. Mergott, Brian A. Willis, Scott A. Monk, Pablo Garcia-Losada, David E. Timm, Richard A. Brier, Jose Eduardo Lopez
Publikováno v:
Journal of medicinal chemistry. 64(12)
The beta-site APP cleaving enzyme 1, known as BACE1, has been a widely pursued Alzheimer's disease drug target owing to its critical role in the production of amyloid-beta. We have previously reported the clinical development of LY2811376 and LY28867
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::698057ee408d2f35c662510d099e51b3
https://pubmed.ncbi.nlm.nih.gov/34081466
https://pubmed.ncbi.nlm.nih.gov/34081466
Autor:
Brian Michael Mathes, Zhixiang Yang, Dustin J. Mergott, Scott A. Monk, Hykop Gevorkyan, Larry Ereshefsky, Vaught Grant Matthews, Leonard L. Winneroski, Jon A. Erickson, Stephen L. Lowe, Celedon Gonzales, Scott Martin Sheehan, David E. Timm, Brian Morgan Watson, Ferenc Martenyi, David O. Calligaro, Stephanie L. Stout, Theresa A. Day, Richard A. Brier, Patrick J Cocke, Brian A. Willis, Stanford Jhee, Leonard N. Boggs, Robert A. Dean, James E. Audia, Steven F. Komjathy, Anthony R. Borders, Terry D. Lindstrom, Patrick C. May, Douglas E. James, Linglin Li
BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of potent and selective inhibitors of BACE1 has been a focu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f78c69adc5fae76e66024d7197aeccfc
https://europepmc.org/articles/PMC6605527/
https://europepmc.org/articles/PMC6605527/
Publikováno v:
Alzheimer's & Dementia. 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e0c9d4903e4d00434006f3f1152e0c7
https://doi.org/10.1016/j.jalz.2008.05.602
https://doi.org/10.1016/j.jalz.2008.05.602